Vietnam is advancing its ambition to become a leading destination for clinical trials in Southeast Asia. A new report outlines a roadmap to position the country among the top three ASEAN clinical trial hubs by 2030. With a population exceeding 100 million and a commitment to innovation, Vietnam offers strong potential in research areas such as oncology, infectious disease, and metabolic disorders. Recent government reforms, including a pledge to invest 2% of GDP in R&D, have laid the groundwork for a stronger research ecosystem.
The report highlights key challenges, including a slow approval process, limited research infrastructure, and a shortage of skilled professionals. To address these, it proposes short-, medium- and long-term measures spanning policy reforms, infrastructure development, workforce training and incentives for investment.
Crucially, the report recommends establishing a national Centre of Excellence and expanding GCP-certified trial units to strengthen capacity. Implementing fast-track approval pathways for internationally approved trials and improving bilingual documentation are also advised.
“Vietnam can significantly enhance its clinical trial capabilities by embracing international best practices… This strategic alignment will not only drive innovation in therapeutic research but also position Vietnam as a regional hub for pioneering life-saving treatments.”
Prof Guy Thwaites, Director, Oxford University Clinical Research Unit